# Perrigo Company plc (PRGO): Healthcare Stock with a 36.65% Potential Upside

- Link: https://www.directorstalkinterviews.com/perrigo-company-plc-prgo-healthcare-stock-with-a-36-65-potential-upside/4121192920
- Published: 2025-04-18T10:06:27+01:00
- Author: Madison Wilson

Perrigo Company plc (PRGO), a leading name in the healthcare sector, particularly
within the niche of specialty and generic drug manufacturing, presents an intriguing
opportunity for investors seeking both stability and growth. Headquartered in Dublin,
Ireland, this company has carved out a substantial market presence, boasting a market
capitalization of $3.46 billion.

Perrigo’s current stock price hovers around $25.32, with its 52-week range stretching
from $23.50 to $33.43. What captivates investor attention is the potential upside
of 36.65%, as indicated by the average analyst target price of $34.60. This optimistic
outlook is supported by a range of analyst ratings, comprising three buy recommendations
and three holds, with no sell ratings—a testament to its resilience and potential
in a competitive sector.

From a valuation perspective, Perrigo’s forward P/E ratio of 7.84 suggests a potentially
undervalued stock, especially in contrast with the broader healthcare sector. However,
certain valuation metrics such as the trailing P/E, PEG, Price/Book, and Price/Sales
ratios are not available, which could pose a challenge for investors seeking a complete
financial picture.

The company’s performance metrics present a mixed bag. Revenue growth has seen a
slight contraction at -1.60%, and the earnings per share (EPS) stands at -1.17, 
reflecting some of the challenges faced in the current market environment. Return
on equity is at -3.54%, which does highlight some concerns regarding profitability
and efficiency. Yet, Perrigo’s robust free cash flow of $425 million is a positive
indicator of its operational health and ability to reinvest in growth or return 
value to shareholders.

Perrigo offers a compelling dividend yield of 4.58%, although the payout ratio of
10,950% raises questions about the [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
of such dividends in the absence of positive net income. This could signal potential
restructuring or strategic pivots in their dividend policy to align with long-term
financial health.

Technical indicators provide additional insights. With the stock trading below both
its 50-day and 200-day moving averages, currently at $26.45 and $26.54 respectively,
it suggests potential resistance levels. The Relative Strength Index (RSI) of 55.82
indicates that the stock is neither overbought nor oversold, providing a neutral
outlook for technical traders. The MACD and signal line, both in negative territory,
hint at a bearish trend, which investors should monitor closely.

Perrigo’s diversified product portfolio, spanning upper respiratory products, nutrition,
digestive health, pain and sleep aids, and more, underscores its strength in consumer
self-care markets across the Americas and internationally. The company’s extensive
brand lineup, including Mederma, Nasonex, and REACH, and its comprehensive distribution
channels ensure robust market penetration and consumer reach.

For investors, Perrigo presents a nuanced opportunity. While certain financial metrics
highlight challenges, the company’s established market position, potential upside,
and strong cash flow indicate underlying strengths. As the healthcare sector continues
to evolve, particularly in consumer-driven self-care, Perrigo remains well-positioned
to leverage its capabilities for future growth. Investors with a keen eye on healthcare
stocks might consider Perrigo a viable candidate for their portfolios, while keeping
abreast of its strategic developments and market dynamics.

Share on: